ArticleMedicine2026
Different categories of soy products and metabolic dysfunction-associated steatotic liver disease in cross-sectional study of NHANES 2007-2020.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although numerous studies have investigated the relationship between soy products and metabolic dysfunction-associated steatotic liver disease (MASLD), the findings have been highly inconsistent. A fundamental reason for this is that prior research has predominantly treated "soy products" as a single, homogeneous exposure variable, overlooking substantial heterogeneity arising from differences in processing methods, consumption purposes, and regional dietary patterns. This study seeks to address this methodological limitation by developing a fine-grained classification framework, which for the first time enables a systematic investigation into the potentially heterogeneous associations between distinct categories of soy products and MASLD in the U.S. population: an epidemiological context marked by low overall soy intake and a predominance of processed soy foods. Using National Health and Nutrition Examination Survey data, this study developed a classification system of soy products based on processing characteristics and consumption purposes. The core analytical approach employed was weighted multivariable logistic regression, which was complemented by subgroup and mediation analyses to comprehensively investigate intercategory differences in these associations. Sensitivity analyses were additionally performed to verify the robustness of the study findings. In a nationally representative U.S. population, different categories of soy products showed heterogeneous associations with MASLD. Future studies need to apply fine-grained classifications based on processing methods and consumption purposes, and explicitly account for population heterogeneity across demographic and lifestyle characteristics. After full adjustment for confounders, only traditional fermented soy products and soy-based functional snacks had significant inverse associations with MASLD, while no consistent links were found for other categories (traditional non-fermented soy products, soy-based meat alternatives, soy protein supplements, foods with soy additives). Mediation analyses additionally revealed that these categories were inversely associated with the outcome, and differed in their mediation patterns; Subgroup analyses showed the strength of these associations differed across population subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.